COMMUNIQUÉS West-GlobeNewswire

Cheapest Compounded Semaglutide Without Insurance in 2026: What "Low-Cost" GLP-1 Pricing Often Excludes — SynergyRx Consumer Analysis
23/01/2026
A consumer pricing framework for "Cheapest Compounded Semaglutide," "Cheapest Compounded Semaglutide Online," and "Cheapest Compounded Semaglutide Pills" — focused on total monthly cost drivers, not endorsements New [...]
River Oaks Treatment Center Appoints New Clinical Director Amid Expansion of Mental Health Services
22/01/2026
RIVERVIEW, Fla., Jan. 22, 2026 (GLOBE NEWSWIRE) -- River Oaks Treatment Center, a leading addiction rehab center near Tampa, has appointed Brianna Hardcastle, LCSW, as its new Clinical Director as it continues to scale [...]
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
22/01/2026
Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE [...]
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
22/01/2026
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“ Anteris ” or the “ Company ”) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to [...]
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
22/01/2026
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR) a global structural heart company committed to designing, [...]
Intuitive Announces Fourth Quarter Earnings
22/01/2026
SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
22/01/2026
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
22/01/2026
CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
22/01/2026
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
22/01/2026
Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is Supported by CMS Category B IDE Coverage MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. ( [...]
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
22/01/2026
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults [...]
Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution
22/01/2026
Chassieu, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm - Amoéba (FR0011051598 - ALMIB) , industrial greentech specialised in the development of natural microbiological solutions based [...]
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
22/01/2026
4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to Therapy NEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path , a company dedicated to personalizing cancer care through a novel, physics-inspired [...]
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
22/01/2026
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”) today announced that it adjourned its annual and special meeting of shareholders (the “ Meeting [...]
What Are the Top Customer Experience Trends for 2026? New Transcom Report Identifies Five Paradoxes CX Leaders Must Address
22/01/2026
Report explains how enterprises should use AI, automation, and human expertise together to close the Experience Gap Denver CO., Jan. 22, 2026 (GLOBE NEWSWIRE) -- As enterprises evaluate how artificial intelligence will [...]
NARMAFOTINIB Large-Scale Manufactre Complete
22/01/2026
Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial manufacturing [...]
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
22/01/2026
TORONTO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials [...]
Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro’s 2026 Product Catalog
22/01/2026
VANCOUVER, British Columbia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing [...]
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
22/01/2026
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq [...]

Pages